Free Newsletter
China OKs first swine flu vax for production
China's Sinovac Biotech has won swift approval to begin manufacturing the country's first swine flu vaccine. And the regulatory green light will likely be followed up in short order with a second approval.
China is scrambling to head off an expected resurgence of swine flu this fall. Its vast population would easily swamp the country's healthcare system if the pandemic returns with force. A high rate of infection could also easily interfere with the country's huge manufacturing output.
The Chinese are likely to come under intense pressure to donate 10 percent of their production of swine flu vaccine to other countries in the region. The World Health Organization has urged manufacturers to set aside part of their vaccine for lesser developed nations that can't afford to compete with Europe and the U.S. But there will be plenty of local demand for all the vaccine China can produce. Going all out, the country says that its vaccine manufacturers can produce enough vaccine to protect 65 million people this fall--only five percent of its population.
- read the story in the Wall Street Journal
ALSO: Sinovac is negotiating a deal with South Korea's Boryung Pharm to supply the country with swine flu jabs. Report
Related Articles:
Chinese experts clear Sinovac swine flu vax
Baxter, Sinovac racing through swine flu vax trials
Four big vax makers charge ahead with swine flu programs
Billions budgeted for swine flu as programs launch
Vax makers in global race to create swine flu jab
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: